|
|
|
|
|
| First Name: | Mark A. | | Last Name: | Smith | | Title: | Professor | | Advanced Degrees: | Ph.D. | | Affiliation: | Case Western Reserve University | | Department: | Department of Pathology | | Street Address 1: | 2103 Cornell Road | | City: | Cleveland | | State/Province: | OH | | Zip/Postal Code: | 44106 | Country/Territory: | U.S.A. | | Phone: | 216-368-3670 | | Fax: | 216-368-8964 | | Email Address: |  |
Disclosure:
(view policy)
|
Member reports the following financial or other potential conflicts of interest: [Last Modified: 20 September 2010]
I am currently, or have been in the past, a paid speaker and/or consultant for and/or have stock options in Voyager Pharmaceutical Corporation, Panacea Pharmaceutical Company, Neurotez, Neuropharm, Canopus BioPharma, Medivation, Pfizer, Takeda, GlaxoSmithKline, and Eisai.
|
|
|
View all comments by Mark A. Smith
|
Signal transduction, Clinical trials, Protein structure/chemistry, Microscopy, Tau/Cytoskeleton, Neuropathology, A-beta PP/A-beta, Apoptosis/Cell cycle, Neurobiology, Epidemiology, Drug screening, Molecular and Cell biology, Animal Models, Oxidative Stress
|
Dr. Mark A. Smith received his B.Sc. with Honors in Molecular Biology and Biochemistry from Hatfield College, Durham University, England (1986). He went on to earn a Ph.D. in Biochemistry from Nottingham University, England, in 1990. Dr. Smith spent the next two years as a Research Fellow at Sandoz Forschungsinstitut in Vienna, Austria. Presently, he is Professor of Pathology at Case.
The focus of Dr. Smith’s research involves investigating the pathological mechanism(s) underlying selective neuronal death in neurodegenerative diseases such as Alzheimer’s disease. Dr. Smith’s research involves a variety of techniques ranging from histological to molecular biology to cellular models and encompasses diagnostic, mechanistic, and therapeutic strategies. Current projects are directed towards 1) fundamental metabolic alterations; 2) homeostatic dysregulation of transition metals; 3) signal transduction alterations; and 4) inappropriate re-entry into the cell cycle.
Dr. Smith has authored over 800 peer-reviewed manuscripts and chapters and is recognized as one of the top cited researchers in the fields of Neuroscience & Behavior (http://www.in-cites.com/nobel/2007-neu-top100.html), Alzheimer Disease (http://www.esi-topics.com/alzheimer/authors/b1a.html) and Free Radical Biology (http://www.freeradicalscience.com/labs.php). |
Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci. 1997 Apr 15;17(8):2653-7. PMID: 9092586 (627 citations)
Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem. 1997 May;68(5):2092-7.PMID: 9109537 (455 citations)
Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5710-4. PMID: 8202552 (445 citations)
Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N. Oxidative damage in Alzheimer's. Nature. 1996 Jul 11;382(6587):120-1. PMID: 8700201 (434 citations)
Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9866-8. PMID: 9275217 (375 citations)
Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001 Aug;60(8):759-67. PMID: 11487050 (342 citations)
Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott CW, Caputo C, Frappier T, Smith MA, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress.
Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7787-91. PMID: 8052661 (339 citations)
Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci. 1995 Apr;18(4):172-6. PMID: 7778188 (303 citations)
Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, Tabaton M, Perry G. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem. 1998 May;70(5):2212-5. PMID: 9572310 (265 citations)
Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, Smith MA. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci. 1999 Mar 15;19(6):1959-64. PMID: 10066249 (244 citations) |
|
|
|
|
|
|
Home
